Signal transduction by growth factor receptors

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 155-168

  Pawson, Tony ^a   Jorgensen, Claus ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59849094821     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10011-1     Document Type: Chapter

References (161)

1. Heldin C-H, Ostman A, Ronnstrand L Signal transduction via platelet-derived growth factor receptors. Biochemica Biophysica Acta 1998, 1378:F79-F113.
2. Schlessinger J Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211.
3. Heldin CH Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213.
4. Pitcher JA, Freedman NJ, Lefkowitz RJ G protein-coupled receptor kinases. Annu Rev Biochem 1998, 67:653.
5. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835.
6. Beato M, Herrlich P, Schutz G Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83:851.
7. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002, 298:1912.
8. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699.
9. Hubbard SR, Till JH Protein tyrosine kinase structure and function. Annu Rev Biochem 2000, 69:373.
10. Johnson LN, Lewis RJ Structural basis for control by phosphorylation. Chem Rev 2001, 101:2209.
11. Pawson T, Nash P Protein-protein interactions define specificity in signal transduction. Genes Dev 2000, 14:1027.
12. Yaffe MB, Elia AE Phosphoserine/threonine-binding domains. Curr Opin Cell Biol 2001, 13:131.
13. Yaffe MB Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol 2002, 3:177.
14. Walsh CT Posttranslational Modification of Proteins 2006, 1. Roberts and Company, Englewood, Colorado.
15. Seet B, Zhou M-M, Dikic I, et al. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 2006, 7:473.
16. Kuriyan J, Cowburn D Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 1997, 26:259.
17. Waksman G, Shoelson S, Pant N, et al. Binding of a high affinity phosphotyrosyl peptide in the src. Cell 1993, 72:779.
18. Bradshaw JM, Waksman G Molecular recognition by SH2 domains. Adv Protein Chem 2002, 61:161.
19. Songyang Z, Shoelson SE, Chadhuri M, et al. Identification of phosphotyrosine peptide motifs which bind to SH2 domains. Cell 1993, 72:767.
20. Liu BA, Jabonowski K, Raina M, et al. The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol Cell 2006, 22:851.
21. Muslin AJ, Tanner JW, Allen PM, et al. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996, 84:889.
22. Zarrinpar A, Bhattacharyya RP, Lim WA The structure and function of proline recognition domains. Sci STKE 2003, RE8.
23. Strasser A, O'Connor L, Dixit VM Apoptosis signaling. Ann Rev Biochem 2000, 69:217.
24. Cullen PJ, Cozier GE, Banting G, et al. Modular phosphoinositide- binding domains-their role in signaling and membrane trafficking. Curr Biol 2001, 11:R882-R893.
25. Lemmon MA Phosphoinositide recognition domains. Traffic 2003, 4:201.
26. Cronin TC, DiNitto JP, Czech MP, et al. Structural determinants of phosphoinositide selectivity in splice variants of Grp1 family PH domains. EMBO J 2004, 23:3711.
27. Cantley LC The phosphoinositide 3-kinase pathway. Science 2002, 296:1655.
28. Pawson T, Scott JD Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278:2075.
29. Burack WR, Cheng AM, Shaw AS Scaffolds, adaptors and linkers of TCR signaling: theory and practice. Curr Opin Immunol 2002, 14:312.
30. Bhattacharyya RP, Remenyi A, Yeh BJ, et al. Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. Annu Rev Biochem 2006, 75:655.
31. Morrison DK, Davis RJ Regulation of MAP kianse signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 2003, 19:91.
32. Wong W, Scott JD AKAP signaling complexes: focal points in space and time. Nat Rev Mol Cell Biol 2004, 5:959.
33. Dodge-Kafka KL, Soughayer J, Pare GC, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005, 437:574.
34. Etienne-Manneville S, Hall A Rho GTPases in cell biology. Nature 2002, 420:629.
35. Grand RJ, Owen D The biochemistry of ras p21. Biochem J 1991, 279:609.
36. Wittinghofer A Signal transduction via Ras. Biol Chem 1998, 379:933.
37. Boguski MS, McCormick F Proteins regulating Ras and its relatives. Nature 1994, 366:643.
38. Pitcher JA, Freedman NJ, Lefkowitz RJ G protein-coupled receptor kinases. Annu Rev Biochem 1998, 67:653.
39. Sprang SR G protein, effectors and GAPs: structure and mechanism. Curr Opin Struct Biol 1997, 7:849.
40. Weissman AM Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001, 2:169.
41. Pickart CM, Eddins MJ Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 2004, 1695:55.
42. Scheffner M, Nuber U, Huibregtse JM Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 1995, 373:81.
43. Huibregtse JM, Scheffner M, Beaudenon S, et al. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A 1995, 92:5249.
44. Joazeiro CA, Weissman AM RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000, 102:549.
45. Wu G, Xu G, Schulman BA, et al. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF (beta-TrCP1) ubiquitin ligase. Mol Cell 2003, 11:1445.
46. Pinto D, Clevers H Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res 2005, 306:357.
47. Nusse R Wnt signaling in disease and in development. Cell Res 2005, 15:28.
48. Hicke L, Schubert HL, Hill CP Ubiquitin-binding domains. Nat Rev Mol Cell Biol 2005, 6:610.
49. Haglund K, Dikic I Ubiquitylation and cell signaling. EMBO J 2005, 24:3353.
50. Haglund K, Sigismund S, Polo S, et al. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 2003, 5:461.
51. Huang F, Kirkpatrick D, Jiang X, et al. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 2006, 21:737.
52. Schmidt MH, Dikic I The Cbl interactome and its functions. Nat Rev Mol Cell Biol 2005, 6:907.
53. Weinmaster G Notch signal transduction: a real rip and more. Curr Opin Genet Dev 2000, 10:363.
54. Nakayama KI, Nakayama K Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6:369.
55. Backer JM, Myers MG, Shoelson SE, et al. Phosphatidylinositol 3?-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 1992, 11:3469.
56. Manning BD Balancing Akt with S6K: implications for both metabolic diseases and turmorigenesis. J Cell Biol 2004, 167:399.
57. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3 signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213.
58. Harrington LS, Findlay GM, Lamb RF Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem 2005, 30:35.
59. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase acts as a direct target of Ras. Nature 1994, 370:527.
60. Ma L., Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179.
61. Hunter T Signaling-2000 and beyond. Cell 2000, 100:113.
62. Qian D, Weiss A T cell antigen receptor signal transduction. Curr Opin Cell Biol 1997, 9:205.
63. Brown MT, Cooper JA Regulation, substrates and functions of Src. Biochem Biophys Acta 1996, 1287:121.
64. Smith CI, Islam TC, Mattsson PT, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays 2001, 23:436.
65. Levy DE, Darnell JE Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651.
66. Pendergast AM The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 2002, 85:51.
67. Brunton VG, MacPherson IR, Frame MC Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochim Biophys Acta 2004, 1692:121.
68. Burgess AW, Cho HS, Eigenbrot KC, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12:541.
69. Schlessinger J Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669.
70. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127.
71. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu. Science 1987, 235:177.
72. Adams GP, Weiner LM Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147.
73. Huse M, Kuriyan J The conformational plasticity of protein kinases. Cell 2002, 109:275.
74. Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137.
75. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003, 112:859.
76. Burgess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005, 102:3395.
77. Santoro M, Carlomagno F, Romano A, et al. Activation of RET. Science 1995, 267:381.
78. Marengere LEM, Songyang Z, Gish GD, et al. SH2 domain specificity and activity modified by a single residue. Nature 1994, 369:502.
79. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site of the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001, 8:995.
80. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006, 66:283.
81. White MF The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998, 182:3.
82. Backer JM, Schroeder GG, Kahn CR, et al. Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation. J Biol Chem 1992, 267:1367.
83. Sun XJ, Crimmins DL, Myers MG, et al. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol 1993, 13:7418.
84. Wolf G, Trub T, Ottinger E, et al. PTB domains of IRS-1 and Shc have distinct but overlapping binding specificities. J Biol Chem 1995, 270:27407-27410.
85. Chan AC, Shaw AS Regulation of antigen receptor signal transduction by protein tyrosine kinases. Curr Opin Immunol 1996, 8:394.
86. Neumeister EN, Zhu Y, Richard S, et al. Binding of ZAP-70 to phosphorylated T-cell receptor zeta and eta enhances its autophosphorylation and generates specific binding sites for SH2 domain-containing proteins. Mol Cell Biol 1995, 15:3171.
87. DeFranco AL Transmembrane signaling by antigen receptors of B and T lymphocytes. Curr Opin Cell Biol 1995, 7:163.
88. Arpaia E, Shahar M, Dadi H, et al. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 1994, 76:947.
89. Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994, 264:1596.
90. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003, 426:454.
91. Rowley JD Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290.
92. Wong S, Witte ON The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004, 22:247.
93. McWhirter JR, Galasso DL, Wang JY A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993, 13:7587.
94. Puil L, Liu X, Gish G, et al. BCR-ABL oncoproteins bind directly to activators of the ras signalling pathway. EMBO J 1994, 13:764.
95. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993, 75:175.
96. Taniguchi T Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995, 268:251.
97. Darnell JE, Kerr IM, Stark GR Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415.
98. Silva CM Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23:8017.
99. Chen X, Vinkemeier U, Zhao Y, et al. Crystal structure of tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998, 93:827.
100. Mao X, Ren Z, Parker GN, et al. Structural basis of unphosphorylated STAT1 association and receptor binding. Mol Cell 2005, 17:761.
101. Wormald S, Hilton DJ Inhibitors of cytokine signal transduction. J Biol Chem 2004, 279:821.
102. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144.
103. Shannon K, Van Etten RA JAKing up hematopoietic proliferation. Cancer Cell 2005, 7:291.
104. Roux PP, Blenis J ERK and p38 MAPK-activated kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320.
105. Kolch W Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351:289.
106. Whitmarsh AJ, Davis RJ Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Trends Biochem Sci 1998, 23:481.
107. Rozakis-Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF-receptor to mSos1, an activator of Ras. Nature 1993, 363:83.
108. Li N, Batzer A, Daly R, et al. Guanine nucleotide releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signaling. Nature 1993, 363:85.
109. Margarit SM, Sondermann H, Hall BE, et al. Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 2003, 112:685.
110. Resh MD Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Cell Signal 1996, 8:403.
111. Wittinghofer A, Pai EF The structure of Ras protein: a model for a universal molecular switch. Trends Biochem Sci 1991, 16:382.
112. Marshall CJ Ras effectors. Curr Opin Cell Biol 1996, 8:197.
113. Wittinghofer A, Nassar N How Ras-related proteins talk to their effectors. Trends Biochem Sci 1996, 21:488.
114. Hallberg B, Rayter SI, Downward J Interaction of Ras and Raf in intact mammalian cell upon extracellular stimulation. J Biol Chem 1994, 269:3913.
115. Chong H, Vikis HG, Guan KL Mechanisms of regulating the Raf kinase family. Cell Signal 2003, 15:463.
116. Morrison DK, Cutler RE The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997, 9:174.
117. Chong H, Lee J, Guan KL Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 2001, 20:3716.
118. Abraham D, Podar K, Pacher M, et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 2000, 275:22300-22304.
119. Jaumot M, Hancock JF Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 2001, 20:3949.
120. Morrison DK KSR, a MAPK scaffold of the Ras pathway. J Cell Sci 2001, 114:1609.
121. Kolch W Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005, 6:827.
122. Mason CS, Springer CJ, Cooper RG, et al. Serine and tyrosine phosphorylation cooperate in Raf-1, but not B-Raf activation. EMBO J 1999, 18:2137.
123. Chen Z, Gibson TB, Robinson F, et al. MAP kinases. Chem Rev 2001, 101:2449.
124. Tanoue T, Nishida E Molecular recognitions in the MAP kinase cascades. Cell Signal 2003, 15:455.
125. Tanoue T, Adachi M, Moriguchi T, et al. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2000, 2:110.
126. Downward J Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11.
127. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949.
128. Barbacid M Ras oncogenes: their role in neoplasia. Eur J Clin Invest 1990, 20:225.
129. Cichowski K, Jacks T NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593.
130. Wan PT, Garnett MJ, Roe SM, et al. Cancer Genome Project: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic muations of B-RAF. Cell 2004, 116:855.
131. Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005, 20:963.
132. Rodriguez-Viciana P, Sabatier C, et al. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004, 24:4943.
133. Gonzales-Garcia A, Pritchard CA, Paterson HF, et al. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 2005, 7:219.
134. Bai Y, Edamatsu H, Maeda S, et al. Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res 2004, 64:8808.
135. Malliri A, van der Kammen RA, Clark K, et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 2002, 417:867.
136. Songyang Z, Shoelson SE, Chaudhuri M, et al. SH2 domains recognize specific phosphopeptide squences. Cell 1993, 72:767.
137. Yu J, Wiasow C, Backer JM Regulation of the p85/p110a phosphatidylinositol 3?-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J Biol Chem 1998, 273:30199-30203.
138. Yu J, Zhang Y, McIlroy J, et al. Regulation of the p85/p110 phosphatidylinositol 3?-kinase:stabilization and inhibition of the p110a catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998, 18:1379.
139. Maehama T, Dixon JE The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273:13375-13378.
140. DiNitto JP, Cronin TC, Lambright DG Membrane recognition and targeting by lipid-binding domains. Science 2003, re16.
141. Thomas CC, Deak M, Alessi DR, et al. High-resolution structure of the pleckstrin homology domain of protein kinase B/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 2002, 12:1256.
142. James SR, Downes CP, Gigg R, et al. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J 1996, 315:709.
143. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7:261.
144. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277:567.
145. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098.
146. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648.
147. Potter CJ, Pedraza LG, Xu T Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002, 4:658.
148. Manning BD, Tee AR, Logsdon MN, et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002, 10:151.
149. Inoli K, Zhu T, Guan KL TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577.
150. Wullschleger S, Loewith R, Hall MN TOR signaling in growth and metabolism. Cell 2006, 124:471.
151. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002, 16:1472.
152. Hay N, Sonenberg N Upstream and downstream of mTOR. Genes Dev 2004, 18:1926.
153. Engelman JA, Luo J, Cantley LC The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606.
154. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231.
155. del Peso L, Gonzales-Garcia M, Page C, et al. Interleukin-3-indeuced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687.
156. L. Cell 1996, 87:619.
157. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499.
158. Sears R, Nuckolls F, Haura E, et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000, 14:2501.
159. Luo J, Manning BD, Cantley LC Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257.
160. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
161. Shaw RJ Cantley LC. Ras,PI(3)K and mTOR signalling controls tumour cell growth. Nature 20606;441:424 .